Galectin shares crater on NASH analysis; Cellectis sells subsidiary, concentrates on CAR-T;

@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech

@JohnCFierce: Resurgent Merck to accelerate R&D spending in H2, hunt new drug deals. Article | Follow @JohnCFierce

@DamianFierce: $GSK has launched Tanzeum (albiglutide) in the U.S., further crowding the GLP-1 market for T2 diabetes. Press release | Follow @DamianFierce

@EmilyMFierce: Really cool, albeit potentially terrifying: Teeth Sprout from Glia-Derived Stem Cells. GEN piece | Follow @EmilyMFierce

> Shares of Galectin Therapeutics ($GALT) plunged more than 50% Tuesday morning after the little biotech posted disappointing results from a Phase I cohort analysis of its NASH therapy GR-MD-02. Release (PDF)

> Completing its reorganization to focus on CAR-T tech, Paris-based Cellectis said today that it has sold its subsidiary Cellectis AB to Japan's Takara Bio. Release

> Plantation, FL-based Neurotrope initiated a Phase IIa clinical trial to evaluate bryostatin for the treatment of patients with Alzheimer's disease. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Google wearables to add to planned bioinformatics database. Article | Follow @FierceMedDev

@StacyALawrence: Medtronic teaming up with China's LifeTech to develop cardiovascular products. More | Follow @StacyALawrence

@VarunSaxena2: FDA final guidance modifies 510(k) rules, discourages use of multiple predicate devices. Story | Follow @VarunSaxena2

@MichaelGFierce: Scientists test a Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer. More from Newswise | Follow @MichaelGFierce

@EmilyWFierce: FDA and physicians question the validity of popular mobile medical health apps. More from Wired | Follow @EmilyWFierce

> Wearable optical device detects diabetic complication. More

> Proteus Digital adds $52M to Series G, bringing total to $172M. News

> French devicemaker faces FDA scrutiny for prostate cancer device. Article

Pharma News

@FiercePharma: Why are Anoro & Breo slow starters? GSK's new quota-free model, critics say. More | Follow @FiercePharma

@TracyStaton: On Pfizer, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. Release | Follow @TracyStaton

@EricPFierce: Impax shares take a thrashing after FDA issues Taiwan plant new Form 483 with 10 observations. Article | Follow @EricPFierce

@CarlyHFierce: Merck spokeswoman: Sales layoffs to hit PA-based field reps. Story | Follow @CarlyHFierce

> AstraZeneca rolls out preemie newspaper ads to fight Synagis limits. More

> Merck beats Q2 earnings estimates, but mostly on cost-cutting. Story

> Beyond the Q2 numbers, three big questions for Pfizer. Article

Biotech Research News

> NIH to spur innovation in new therapeutic areas. News

> Janssen rethinks drug discovery in a changing R&D environment. More

> Anti-inflammatory drug stops Parkinson's neuron loss in rats. Article

> CDC takes steps to improve lab safety after anthrax, flu scares. Story

> Vaccine protects animals against dust mite allergies. Item

Pharma Manufacturing News

> Impax now faces FDA issues at Taiwan plant that could affect Rytary. Report

> PCI buys contract manufacturer Penn Pharma in $215M deal. Story

> Merck KGaA to cut carbon dioxide emissions at Darmstadt site. More

> Hikma buys closed Boehringer plant and strips out equipment. News

> J&J done with Boehringer plant after building a supply of Doxil. Article

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Vertex is keeping mum on exact details but, as with the rest of its biopharma peers, is seeing trial disruption due to the COVID-19 pandemic.

Companies including Novartis and Pfizer are contributing to the joint response through actions including the sharing of proprietary compounds